Heart failure market could surpass ‘$22bn by 2028’
Due to the aging global population, recent years have seen an increased prevalence of chronic HF.
Read More
Tag: SGLT inhibitor
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
